These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38833322)

  • 41. Network controllability-based algorithm to target personalized driver genes for discovering combinatorial drugs of individual patients.
    Guo WF; Zhang SW; Feng YH; Liang J; Zeng T; Chen L
    Nucleic Acids Res; 2021 Apr; 49(7):e37. PubMed ID: 33434272
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tree-based machine learning algorithms identified minimal set of miRNA biomarkers for breast cancer diagnosis and molecular subtyping.
    Sherafatian M
    Gene; 2018 Nov; 677():111-118. PubMed ID: 30055304
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Delivering on the promise of precision cancer medicine.
    Berger MF; Van Allen EM
    Genome Med; 2016 Oct; 8(1):110. PubMed ID: 27782852
    [No Abstract]   [Full Text] [Related]  

  • 44. Breast cancer subtypes: morphologic and biologic characterization.
    Masood S
    Womens Health (Lond); 2016 Jan; 12(1):103-19. PubMed ID: 26756229
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Precision medicine in oncology].
    Mack E
    Inn Med (Heidelb); 2024 Mar; 65(3):194-201. PubMed ID: 37921995
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bioinformatics workflows for clinical applications in precision oncology.
    Jäger N
    Semin Cancer Biol; 2022 Sep; 84():103-112. PubMed ID: 33476720
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Making Sense of Genetic Information: The Promising Evolution of Clinical Stratification and Precision Oncology Using Machine Learning.
    Baptiste M; Moinuddeen SS; Soliz CL; Ehsan H; Kaneko G
    Genes (Basel); 2021 May; 12(5):. PubMed ID: 34065872
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Platform-Independent Classification System to Predict Molecular Subtypes of High-Grade Serous Ovarian Carcinoma.
    Shilpi A; Kandpal M; Ji Y; Seagle BL; Shahabi S; Davuluri RV
    JCO Clin Cancer Inform; 2019 Apr; 3():1-9. PubMed ID: 31002564
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Delivering precision medicine in oncology today and in future-the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO).
    Ciardiello F; Arnold D; Casali PG; Cervantes A; Douillard JY; Eggermont A; Eniu A; McGregor K; Peters S; Piccart M; Popescu R; Van Cutsem E; Zielinski C; Stahel R
    Ann Oncol; 2014 Sep; 25(9):1673-1678. PubMed ID: 24950979
    [No Abstract]   [Full Text] [Related]  

  • 50. Molecular Tumor Boards in Clinical Practice.
    Luchini C; Lawlor RT; Milella M; Scarpa A
    Trends Cancer; 2020 Sep; 6(9):738-744. PubMed ID: 32517959
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Open questions and controversies in the systemic treatment of breast cancer.
    Barrios CH; Reinert T
    Curr Opin Oncol; 2021 Nov; 33(6):591-596. PubMed ID: 34419955
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).
    Mateo J; Chakravarty D; Dienstmann R; Jezdic S; Gonzalez-Perez A; Lopez-Bigas N; Ng CKY; Bedard PL; Tortora G; Douillard JY; Van Allen EM; Schultz N; Swanton C; André F; Pusztai L
    Ann Oncol; 2018 Sep; 29(9):1895-1902. PubMed ID: 30137196
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Beyond blood: Advancing the frontiers of liquid biopsy in oncology and personalized medicine.
    Bao Y; Zhang D; Guo H; Ma W
    Cancer Sci; 2024 Apr; 115(4):1060-1072. PubMed ID: 38308498
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Genetic heterogeneity in breast cancer: the road to personalized medicine?
    Baird RD; Caldas C
    BMC Med; 2013 Jun; 11():151. PubMed ID: 23800221
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of a Collaboration Between a Health Plan, Oncology Practice, and Comprehensive Genomic Profiling Company from the Payer Perspective.
    Reitsma M; Fox J; Borre PV; Cavanaugh M; Chudnovsky Y; Erlich RL; Gribbin TE; Anhorn R
    J Manag Care Spec Pharm; 2019 May; 25(5):601-611. PubMed ID: 30632889
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pediatric oncology enters an era of precision medicine.
    Seibel NL; Janeway K; Allen CE; Chi SN; Cho YJ; Glade Bender JL; Kim A; Laetsch TW; Irwin MS; Takebe N; Tricoli JV; Parsons DW
    Curr Probl Cancer; 2017; 41(3):194-200. PubMed ID: 28343740
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Definitions and statistical properties of master protocols for personalized medicine in oncology.
    Renfro LA; Mandrekar SJ
    J Biopharm Stat; 2018; 28(2):217-228. PubMed ID: 28877008
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Giving Up on Precision Oncology? Not So Fast!
    Warner JL
    Clin Transl Sci; 2017 May; 10(3):128-129. PubMed ID: 28146309
    [No Abstract]   [Full Text] [Related]  

  • 59. Epigenetics and Precision Oncology.
    Werner RJ; Kelly AD; Issa JJ
    Cancer J; 2017; 23(5):262-269. PubMed ID: 28926426
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Precision medicine beyond medical oncology: using molecular analysis to guide treatments of colorectal neoplasia.
    Molloy MP; Engel A
    Expert Rev Gastroenterol Hepatol; 2018 Dec; 12(12):1179-1181. PubMed ID: 30791786
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.